XTRA:BAYNPharmaceuticals
Is Bayer (XTRA:BAYN) Undervalued As AMBELVIST Approval And Pipeline Progress Lift Interest?
Bayer (XTRA:BAYN) is back in focus after U.S. regulators approved its new MRI contrast agent AMBELVIST, and the company moved forward on multiple fronts in research partnerships and oncology development.
See our latest analysis for Bayer.
Recent gains around the AMBELVIST approval and AI drug discovery partnership come on top of a 4.96% 7 day share price return and a 50.41% total shareholder return over the past year, while longer term total shareholder returns over three and five years...